Fact-checked by the Peptide Authority Editorial Board · Last reviewed:
What Is Epitalon? Benefits, Research & Safety
A synthetic tetrapeptide based on epithalamin, researched for its potential effects on telomerase activation and biological ageing.
Also known as:
Epithalon
Epithalone
AGAG
UK summary: Not a licensed UK medicine. A short tetrapeptide investigated almost exclusively in Russian studies for telomerase-related anti-ageing endpoints. Findings have not been broadly replicated by independent groups; human evidence is limited.
Quick Facts
Category
Longevity & Anti-Ageing
Half-Life
Limited pharmacokinetic data available
UK Status
Not licensed for human use. Research compound only.
EU Status
Not approved for therapeutic use.
Overview
Epitalon (also spelled Epithalon) is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly. It was developed based on epithalamin, a peptide extract from the pineal gland originally studied by Russian scientist Professor Vladimir Khavinson.
The primary research interest in Epitalon centres on its reported ability to activate telomerase, the enzyme responsible for maintaining telomeres—the protective caps at the ends of chromosomes. Telomere shortening is associated with cellular ageing and senescence, making telomerase activation a target of longevity research.
Studies, primarily from Russian research groups, have suggested that Epitalon may extend lifespan in animal models, improve various biomarkers of ageing, and potentially have positive effects on immune function, circadian rhythms, and neuroendocrine regulation.
However, it should be noted that much of the research on Epitalon has been published in Russian journals or older literature, with limited replication by independent Western research groups. The quality and methodology of some studies have been questioned. While the concept of telomerase activation for anti-ageing is scientifically plausible, the specific evidence for Epitalon requires more rigorous investigation.
Epitalon is not approved for therapeutic use and remains a research compound.
Evidence standards summary
Epitalon — evidence and risk at a glance
Twenty standard modules scored against the Peptide Authority evidence grading methodology. Missing modules indicate the field has not yet been characterised editorially — treat absences as uncertainty rather than reassurance.
01Evidence snapshot
DAnimal/cell evidence onlyOverall grade against our evidence grading methodology.
Not a licensed UK medicine. A short tetrapeptide investigated almost exclusively in Russian studies for telomerase-related anti-ageing endpoints. Findings have not been broadly replicated by independent groups; human evidence is limited.
02Human evidence grade
ETheoretical / insufficientStrength of evidence from published human trials.
03Preclinical evidence grade
DAnimal/cell evidence onlyAnimal-model and in-vitro evidence quality.
04Regulatory status
- UK: Not licensed for human use. Research compound only.
- EU: Not approved for therapeutic use.
- Notes: Epitalon is not approved by any major regulatory authority. Much of the research originates from Russian institutions with limited independent replication. Any use is experimental with unknown risks.
05Approved medical uses
None in the UK or EU as a finished medicine. (Or: not yet documented; treat as absence rather than approval.)
06Unapproved / promotional claims
- Reverses biological ageing by lengthening telomeres.
- Extends human lifespan by 20-30%.
- Cures or prevents age-related disease.
- Safe for indefinite daily use.
07Common internet claims
- Marketed as the telomere-lengthening anti-ageing peptide.
- Sold in cycled protocols based on rodent and Russian-clinical-study extrapolation.
- Promoted in longevity stacks alongside NAD+, rapamycin, and metformin.
08Claim vs evidence
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Extends human lifespan via telomere lengthening” | D | Limited | High | Russian-language studies report telomere-related effects; independent replication is limited and lifespan claims in humans are not established. |
| “Reverses biological ageing” | E | No | High | There is no UK-licensed indication for ageing reversal. |
| “Safe — no serious adverse events” | E | No | High | Systematic long-term safety data is lacking. Telomerase activation has a theoretical cancer-promotion concern that is not fully resolved. |
09Safety uncertainty score
High
Limited human safety data; meaningful uncertainty about rare or long-term effects.
10Known adverse signals
- Limited systematic safety data — most reports are anecdotal.
- Theoretical cancer-promotion risk from telomerase activation in pre-malignant cells.
- Injection site reactions.
- Unknown chronic effects on melatonin or circadian-rhythm pathways.
11Drug-interaction uncertainty
High
Interaction picture sparse; meaningful uncertainty when combined with other medicines.
12Anti-doping status
WADA: Sport status unclearWADA strict-liability framing applies.
13UK legal position
UK: Sold as 'research only' (UK)
Not licensed for human use. Research compound only.
Read the full UK legal guide → Are peptides legal in the UK?
14EU legal position
Not approved for therapeutic use.
15What this page cannot tell you
- Whether a UK-purchased vial actually contains Epitalon at the labelled concentration.
- Whether telomere lengthening in a Petri dish translates to longevity in humans.
- What the cancer risk profile is over decades of intermittent use.
- How it interacts with statins, metformin, or other longevity stack drugs.
16Last reviewed
17Citation quality score
DAnimal/cell evidence onlyQuality of the sources we cite, graded against the evidence grading methodology.
18Research gaps
- Most positive human data comes from a single Russian research group.
- No independent Western replication of lifespan or telomere findings.
- No registered Phase 3 trials anywhere in the world.
- Long-term oncologic surveillance does not exist.
19Safer alternatives / established care pathways
- Evidence-based longevity interventions: regular aerobic exercise, resistance training, Mediterranean-style diet, sleep, smoking cessation.
- NHS cardiovascular and metabolic-risk assessment to address modifiable longevity factors.
- Routine cancer-screening uptake (cervical, breast, bowel) — the highest-impact longevity intervention available in the UK.
20Doctor discussion prompts
Questions to ask a qualified clinician
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is Epitalon a licensed UK medicine?
- What is the quality of the existing evidence beyond Russian studies?
- What theoretical concerns exist around telomerase activation and cancer biology?
- If I'm an athlete, what is the WADA position on Epitalon?
Discovery & History
Epitalon's development originated from research conducted at the Saint Petersburg Institute of Bioregulation and Gerontology in Russia, led by Professor Vladimir Khavinson. Beginning in the 1970s and 1980s, Khavinson investigated "bioregulatory peptides"—short peptides isolated from various organs that he believed could regulate organ-specific functions.
Epithalamin, a peptide extract from bovine pineal gland, was among these compounds. Research suggested it could influence circadian rhythms, melatonin production, and potentially ageing processes. Epitalon was developed as a synthetic tetrapeptide intended to replicate the active component of epithalamin.
Studies in the 1990s and 2000s, primarily published by Russian researchers, reported lifespan extension in animal models, telomerase activation in cell culture, and various age-related biomarker improvements. Professor Khavinson and colleagues published extensively on these findings.
The research garnered international attention, particularly in longevity and biohacking communities, though the work has not been widely replicated by independent groups. The peptide remains a subject of ongoing research interest, though more rigorous, peer-reviewed studies are needed to validate earlier claims.
Mechanism of Action
The proposed mechanisms of Epitalon action include:
**Telomerase Activation**
Epitalon is reported to activate telomerase, the enzyme that can elongate telomeres—the protective DNA sequences at chromosome ends. Telomere shortening is associated with cellular ageing and limited replicative capacity. By activating telomerase, Epitalon may theoretically extend cellular lifespan and delay senescence.
**Pineal Gland Effects**
As a synthetic version of a pineal-derived peptide, Epitalon may influence pineal function, potentially affecting melatonin production and circadian rhythm regulation. The pineal gland's function typically declines with age.
**Neuroendocrine Regulation**
Research suggests possible effects on various neuroendocrine functions, though specific mechanisms are not fully elucidated.
**Antioxidant Effects**
Some studies suggest Epitalon may have antioxidant properties, potentially reducing oxidative stress associated with ageing.
**Immune Function**
Research has suggested possible immunomodulatory effects, though mechanisms and clinical relevance are uncertain.
It should be emphasised that while these mechanisms are biologically plausible, the evidence supporting Epitalon's effects in humans remains limited and requires further validation.
Researched Benefits
Based on preclinical and clinical research findings:
- 1Telomerase activation observed in cell culture studies
- 2Lifespan extension reported in some animal models
- 3Possible positive effects on circadian rhythm regulation
- 4Potential antioxidant properties
- 5Suggested improvement in age-related biomarkers (requires validation)
- 6Possible effects on melatonin production
Claim vs Evidence
How popular claims about Epitalon stack up against the current research, graded using our public evidence grading methodology.
| Claim | Evidence | Human evidence? | Regulatory concern | Safer wording |
|---|---|---|---|---|
| “Extends human lifespan via telomere lengthening” | D | Limited | High | Russian-language studies report telomere-related effects; independent replication is limited and lifespan claims in humans are not established. |
| “Reverses biological ageing” | E | No | High | There is no UK-licensed indication for ageing reversal. |
| “Safe — no serious adverse events” | E | No | High | Systematic long-term safety data is lacking. Telomerase activation has a theoretical cancer-promotion concern that is not fully resolved. |
Theoretical Dosing & Protocols
⚠️ Educational Only: The following information is derived from research literature and is not a prescription or recommendation. No standardised human dosing exists. Always consult a qualified healthcare professional.
| Theoretical Dosage | 5-10 mg daily (based on research protocols and anecdotal reports) |
| Frequency | Daily for cycles of 10-20 days, repeated periodically |
| Duration | Cycled use with breaks; long-term protocols undefined |
| Notes | These are theoretical protocols based on limited research and anecdotal information. Epitalon is not approved for human use. The quality of available products varies significantly, and any use carries unknown risks. |
Administration Routes
Routes studied in research settings (educational only):
- Subcutaneous injection (most common in research)
- Intramuscular injection
| Half-Life | Stability |
|---|---|
| Limited pharmacokinetic data available | Lyophilised powder should be stored refrigerated or frozen |
Safety Profile & Known Risks
Commonly Reported Side Effects
- Limited systematic safety data available
- Injection site reactions
Rare Risks & Concerns
- Unknown long-term effects
- Theoretical concerns about uncontrolled cell division
- Effects on existing malignancies unknown
Contraindications
- Active cancer (theoretical risk of promoting tumour cell survival)
- Pregnancy and breastfeeding
- Autoimmune conditions
- Children and adolescents
UK & EU Regulatory Context
🇬🇧 United Kingdom
Not licensed for human use. Research compound only.
🇪🇺 European Union
Not approved for therapeutic use.
Epitalon is not approved by any major regulatory authority. Much of the research originates from Russian institutions with limited independent replication. Any use is experimental with unknown risks.
Clinical Studies Summary
Peptide Bioregulators: A New Class of Geroprotectors
Review of bioregulatory peptides including epithalamin and Epitalon, primarily from Russian research groups.
Adv Gerontol. Various publicationsView on PubMed
Telomerase Activation by Epithalamin
Cell culture study suggesting telomerase activation by epithalamin/Epitalon.
Bull Exp Biol Med. 2003View on PubMed
Looking for Epitalon?
Source research-grade Epitalon from a trusted UK supplier — third-party tested with certificate of analysis.
View at SupplierFrequently Asked Questions
Questions to ask a qualified clinician about Epitalon
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Is Epitalon a licensed UK medicine?
- What is the quality of the existing evidence beyond Russian studies?
- What theoretical concerns exist around telomerase activation and cancer biology?
- If I'm an athlete, what is the WADA position on Epitalon?
UK regulatory & safety context
Related Research Guides
Related Peptides
GHK-Cu
A naturally occurring copper-binding tripeptide researched for its roles in wound healing, skin regeneration, anti-ageing, and tissue remodelling.
Learn moreMOTS-c
A mitochondrial-derived peptide that regulates metabolic homeostasis and exercise adaptations, representing a novel class of signalling molecules.
Learn moreThymosin Alpha-1
A thymic peptide with potent immunomodulatory properties, approved in some countries for treating viral hepatitis and as an immune adjuvant.
Learn more